NanoViricides Ships NV-387 Oral Gummies to DRC for Phase II MPox Trial

NanoViricides, Inc. (NYSE American: NNVC) announced that it has shipped NV-387 Oral Gummies to the Democratic Republic of Congo (DRC) in preparation for a Phase II clinical trial evaluating the drug as a treatment for MPox. The company said site preparations are being conducted by its contract research organization, Om Sai Clinical Research Pvt. Ltd., and local partners, with patient enrollment and dosing expected to begin following completion of staff training in the coming weeks.

The trial will assess the safety and effectiveness of NV-387 in patients with MPox caused by human monkeypox virus infection, primarily the more severe Clade I strain endemic to the DRC. The company also noted that NV-387, a broad-spectrum antiviral candidate, has been proposed for evaluation against Ebola virus infections and that the shipment makes the drug locally available should it be utilized in response efforts. NanoViricides believes successful clinical development of NV-387 could position the therapy as a potential treatment option for multiple viral diseases, including MPox and Ebola.

This shipment marks a critical step in advancing NV-387 into human trials. The drug candidate has shown promise in preclinical studies against a range of viruses, including respiratory syncytial virus (RSV), COVID-19, influenza, and MPox. According to the company, NV-387 is a nanoviricide that uses a novel mechanism to target viruses directly, potentially offering a broad-spectrum treatment option for emerging viral threats.

The DRC has been battling a severe outbreak of MPox, with the Clade I strain associated with higher mortality rates. The World Health Organization has declared MPox a public health emergency of international concern, underscoring the need for effective treatments. NanoViricides' Phase II trial aims to enroll patients at multiple sites in the DRC, with support from local health authorities and international collaborators.

In addition to MPox, NanoViricides is exploring NV-387 for other viral diseases. The company has stated that the drug could be evaluated against Ebola virus infections, given its broad-spectrum activity. The availability of NV-387 in the DRC may facilitate rapid deployment if needed for Ebola response efforts, though no specific plans have been announced.

The successful development of NV-387 would represent a significant advancement in antiviral therapy, offering a potential treatment for diseases that currently lack effective options. NanoViricides continues to advance its pipeline, including NV-HHV-1 for shingles and other candidates for herpes, influenza, and HIV. The company's platform technology, licensed from TheraCour Pharma, focuses on creating nanomedicines that target viruses with high specificity.

For more information on NanoViricides and its pipeline, visit the company's newsroom at https://ibn.fm/NNVC.